Artículos por temáticas

Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis

Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, Leyhe T, Turana Y, Lee IR, Yoon JH, Shin JI.

Mol Neurobiol. 2017 Nov;54(9):7297-7311. doi: 10.1007/s12035-016-0192-9. Epub 2016 Nov 4.

Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field-An Opinion

Twyman RE.

Neurochem Res. 2017 Jul;42(7):2099-2115. doi: 10.1007/s11064-017-2300-2. Epub 2017 Jun 7.

Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease

Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):124-131. doi: 10.1097/FBP.0000000000000292.

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease

Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Lehéricy S, Teipel S, Dubois B, Hampel H; Hippocampus Study Group.

Sci Rep. 2017 Sep 15;7(1):11706. doi: 10.1038/s41598-017-09780-3.

Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G.

Curr Alzheimer Res. 2017;14(11):1155-1163. doi: 10.2174/1567205014666170329113007.

Therapeutic Potentials of Microalgae in the Treatment of Alzheimer's Disease

Olasehinde TA, Olaniran AO, Okoh AI.

Molecules. 2017 Mar 18;22(3):480. doi: 10.3390/molecules22030480.

Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities

Theleritis C, Siarkos K, Katirtzoglou E, Politis A.

J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. doi: 10.1177/0891988716678684.

[Alzheimer's disease and epilepsy]

Haussmann R, Mayer T, Schrempf W, Donix M.

Nervenarzt. 2017 Sep;88(9):1003-1009. doi: 10.1007/s00115-017-0286-2.

Tacrine: In vivo veritas

Jarrott B.

Pharmacol Res. 2017 Feb;116:29-31. doi: 10.1016/j.phrs.2016.12.033. Epub 2016 Dec 28.

Biosensors for Screening Kinase Inhibitors

Bhalla N, Estrela P.

Curr Top Med Chem. 2017;17(22):2470-2481. doi: 10.2174/1568026617666170531113233.

Role of σ(1) Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia

Maurice T, Goguadze N.

Adv Exp Med Biol. 2017;964:213-233. doi: 10.1007/978-3-319-50174-1_15.

Resveratrol and Amyloid-Beta: Mechanistic Insights

Jia Y, Wang N, Liu X.

Nutrients. 2017 Oct 14;9(10):1122. doi: 10.3390/nu9101122.

Resveratrol for Alzheimer's disease

Sawda C, Moussa C, Turner RS.

Ann N Y Acad Sci. 2017 Sep;1403(1):142-149. doi: 10.1111/nyas.13431. Epub 2017 Aug 16.

Nanotechnology for Alzheimer Disease

Leszek J, Md Ashraf G, Tse WH, Zhang J, Gasiorowski K, Avila-Rodriguez MF, Tarasov VV, Barreto GE, Klochkov SG, Bachurin SO, Aliev G.

Curr Alzheimer Res. 2017;14(11):1182-1189. doi: 10.2174/1567205014666170203125008.

Alzheimer's disease: where next for anti-amyloid therapies?

Hardy J, De Strooper B.

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.